These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37140277)

  • 1. Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.
    Alafnan A; Dogan R; Bender O; Celik I; Mollica A; Malik JA; Rengasamy KRR; Break MKB; Khojali WMA; Alharby TN; Atalay A; Anwar S
    Eur Rev Med Pharmacol Sci; 2023 Apr; 27(8):3270-3287. PubMed ID: 37140277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of an Oxindole Derivative with (-)-β-Elemene Alters Cell Death Pathways in FLT3/ITD
    Alanazi J; Bender O; Dogan R; Malik JA; Atalay A; Ali TFS; Beshr EAM; Shawky AM; Aly OM; Alqahtani YNH; Anwar S
    Molecules; 2023 Jul; 28(13):. PubMed ID: 37446914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.
    Bender O; Shoman ME; Ali TFS; Dogan R; Celik I; Mollica A; Hamed MIA; Aly OM; Alamri A; Alanazi J; Ahemad N; Gan SH; Malik JA; Anwar S; Atalay A; Beshr EAM
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200407. PubMed ID: 36403191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
    Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
    Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
    Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
    Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
    J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
    Yen SC; Chen LC; Huang HL; Ngo ST; Wu YW; Lin TE; Sung TY; Lien ST; Tseng HJ; Pan SL; Huang WJ; Hsu KC
    J Nat Prod; 2021 Jan; 84(1):1-10. PubMed ID: 33393294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
    Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
    Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.
    Yu M; Fang ZX; Wang WW; Zhang Y; Bu ZL; Liu M; Xiao XH; Zhang ZL; Zhang XM; Cao Y; Wang YY; Lei H; Xu HZ; Wu YZ; Liu W; Wu YL
    Acta Pharmacol Sin; 2021 Apr; 42(4):604-612. PubMed ID: 32694757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
    Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H
    Leukemia; 2016 May; 30(5):1025-32. PubMed ID: 26686245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Potent and Selective FLT3 Inhibitor (
    Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
    J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
    Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
    Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.